Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage

Kinerase® Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01885091

Enrollment

100

Registered

2013-06-24

Start date

2012-12-31

Completion date

Unknown

Last updated

2013-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blotchiness, Fine Wrinkles, Mottling, Pigmentation, Skin Roughness

Brief summary

The purpose of the K.I.S.S. study is to evaluate the efficacy of Kinerase® Cream (Kinetin 0.1%) in Thai patients, on the basis of the severity and clinical signs of facial photodamage.

Interventions

OTHERKinerase

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Male and female subjects older than 35 years of age and less than 65 years of age. 2. Subjects with mild, moderate or severe facial photodamage as assessed by a 10-point scale. 3. Subjects willing to sign an informed consent and adhere to all protocol requirements.

Exclusion criteria

1. Male and female subjects with suspected porphyria, systemic or cutaneous erythematosus lupus, or any other photosensitizing disorder or drug-induced photosensitization. 2. Subjects with chronic or recurring skin disease or disorder. 3. Subjects with any active infectious skin disorder (Herpes simplex, molluscum contagiosum, and facial warts). 4. Subjects with skin cancer of the facial tissues. 5. Subjects who have received any laser/ intense pulsed light (IPL) / chemical peel in the 2 months preceding the screening visit. 6. Subjects with a history of topical and/or oral isotretinoin use, 6 months prior to the screening visit. 7. Subjects who have been on topical Retin-A or Renova in the 2 months prior to the screening visit. 8. Subjects who have used topical alpha-hydroxy acid skin care products in the month preceding the screening visit. 9. Subjects currently on any anti-aging products and who wish to continue use of their products. 10. Subjects requiring concurrent treatment that would interfere with the study assessments. 11. Pregnant or lactating female subjects.

Design outcomes

Primary

Measure	Time frame
To assess the physician's evaluation and patient's self-evaluation at 4 weeks.	4 weeks
To assess the physician's evaluation and patient's self-evaluation at 8 weeks.	8 weeks
To assess the physician's evaluation and patient's self-evaluation at 12 weeks.	12 weeks

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026